SequelSEC

ANAPTYSBIO, INC ANAB

Pharmaceutical Preparations · CIK 0001370053 · Fiscal year ends 1231

Revenue
$234.60M
Fiscal year ended 2025-12-31
Operating income
$47.90M
Fiscal year ended 2025-12-31
Free cash flow
$19.61M
Fiscal year ended 2025-12-31

Valuation, from the filing

Public float$432.51MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$14.86Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue1.8×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity11.6×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Operating margin20.4%92th
CapEx / revenue0.0%8th
Revenue YoY growth157.0%87th
FCF margin8.4%78th
Current ratio9.07x77th
SBC / revenue15.4%43th

ANAPTYSBIO, INC (ANAB) reported revenue of $234.60M and net income of -$13.23M for the fiscal year ended 2025-12-31. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from ANAPTYSBIO, INC’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

ANAPTYSBIO, INC income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenue$234.60M$91.28M$17.16M$10.29M$63.18M$75.00M$8.00M$5.00M$10.00M$16.68M
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income$47.90M-$114.95M-$164.41M-$115.15M-$56.81M-$23.88M-$107.43M-$66.72M-$28.78M-$3.02M
Net income-$13.23M-$145.23M-$163.62M-$128.72M-$57.80M-$19.93M-$97.34M-$61.66M-$30.07M-$4.26M
Research & developmentUnavailableUnavailableUnavailable$88.80M$98.50M$80.02M$99.34M$56.20M$29.44M$15.42M
Weighted-average diluted sharesshares 28.76Mshares 28.38Mshares 26.92Mshares 28.16Mshares 27.43Mshares 27.30Mshares 27.06MUnavailableUnavailableUnavailable
Pretax income-$13.07M-$145.23M-$163.62M-$128.70M-$57.80M-$19.93M-$97.49M-$61.85M-$30.07M-$4.26M
Income tax expense$164.00K$3.00K-$4.00K$24.00K$0$0-$152.00K-$192.00K$0$0
Diluted EPS$-0.46$-5.12$-6.08$-4.57$-2.11$-0.73$-3.60$-2.50$-1.52$-1.62
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$50.74M$42.39M$41.95M$36.64M$21.49M$18.85M$16.09M$15.53M$9.34M$4.29M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

ANAPTYSBIO, INC balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Cash & equivalents$238.20M$123.08M$35.96M$71.31M$495.73M$250.46M$171.02M$113.60M$81.19M$51.23M
Total assets$364.40M$483.83M$452.39M$610.38M$643.07M$416.55M$435.20M$509.00M$329.36M$62.18M
Current assets$350.25M$431.88M$406.84M$447.20M$553.88M$396.56M$377.73M$434.22M$252.70M$58.21M
Total liabilitiesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current liabilities$38.62M$45.43M$37.44M$26.05M$16.10M$19.82M$29.54M$21.84M$14.09M$5.71M
Total equity incl. NCI$37.21M$70.87M$88.10M$262.10M$356.43M$396.73M$405.01M$486.36M$307.58M-$38.25M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivable$33.85M$40.76M$6.85M$1.42M$876.00K$0$0$0$0$1.22M
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$3.87M$4.00M$4.70M$2.78M$1.74M$4.22M$16.24M$5.44M$2.32M$2.28M

Cash flow

ANAPTYSBIO, INC cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Operating cash flow$19.70M-$135.34M-$120.80M-$73.59M-$45.92M-$14.16M-$69.52M-$48.51M-$19.44M-$9.03M
Capital expenditures$87.00K$358.00K$807.00K$358.00K$1.37M$569.00K$805.00K$1.06M$290.00K$50.00K
Investing cash flow$228.03M$95.40M$144.75M-$394.84M$38.84M$94.48M$131.43M-$142.45M-$243.06M-$50.00K
Financing cash flow-$132.61M$127.05M-$59.30M$44.02M$252.30M-$879.00K-$4.49M$223.36M$292.45M$8.63M
Net change in cash$115.12M$87.12M-$35.34M-$424.42M$245.21M$79.44M$57.42M$32.41MUnavailableUnavailable
Stock-based compensation$36.07M$34.05M$33.20M$27.36M$15.35MUnavailableUnavailableUnavailable$4.38M$1.16M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchases$68.63M$456.00K$50.00M$0$0UnavailableUnavailable$0$0$1.00K
Depreciation & amortization$559.00K$606.00K$652.00K$675.00K$619.00K$559.00K$514.00K$315.00K$183.00K$233.00K

Derived

ANAPTYSBIO, INC derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Free cash flow$19.61M-$135.70M-$121.61M-$73.95M-$47.29M-$14.73M-$70.32M-$49.57M-$19.73M-$9.08M
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating margin20.4%-125.9%-958.3%-1119.4%-89.9%-31.8%-1342.9%-1334.4%-287.8%-18.1%
FCF margin8.4%-148.7%-708.8%-718.9%-74.8%-19.6%-879.0%-991.4%-197.3%-54.4%
SBC / revenue15.4%37.3%193.5%265.9%24.3%UnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio9.07x9.51x10.87x17.16x34.40x20.01x12.79x19.89x17.93x10.20x
Revenue YoY growth157.0%432.0%66.8%-83.7%-15.8%837.5%60.0%-50.0%-40.1%Unavailable
Net marginUnavailableUnavailableUnavailable-1251.3%-91.5%-26.6%-1216.7%-1233.1%-300.7%-25.5%
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailable106.7%1241.7%1123.9%294.4%92.4%
CapEx / revenue0.0%0.4%4.7%3.5%2.2%0.8%10.1%21.3%2.9%0.3%
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open ANAB in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-05-12View SEC filing
10-K/A · Filed 2026-04-28View SEC filing
10-K · Filed 2026-03-03View SEC filing
10-Q · Filed 2025-11-04View SEC filing
10-Q · Filed 2025-08-06View SEC filing
10-Q · Filed 2025-05-05View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.